| Literature DB >> 21711572 |
Claudio Borghi1, Eugenio R Cosentino, Elisa R Rinaldi, Cristina Brandolini, Maria C Rimondi, Maddalena Veronesi, Arrigo Fg Cicero, Ada Dormi, Antonio Pirodda.
Abstract
BACKGROUND: The complex mechanism responsible for tinnitus, a symptom highly prevalent in elderly patients, could involve an impaired control of the microcirculation of the inner ear, particularly in patients with poor blood pressure control and impaired left ventricular (LV) function.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21711572 PMCID: PMC3141544 DOI: 10.1186/1741-7015-9-80
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Baseline clinical, echocardiographical, and neurohumoral characteristics of the population
| Presence of tinnitus | |||
|---|---|---|---|
| Yes | No | ||
| Male | 122 (52.3%) | 408 (52.6%) | NS |
| Female | 111 (47.7%) | 317 (47.4%) | NS |
| Ethiology of CHF (%) | |||
| Hypertension | 30.0 | 31.7 | NS |
| Ischemic | 41 | 40 | NS |
| CMP | 23.3 | 24.3 | NS |
| Valve disease | 3.7 | 3 | NS |
| Other | 2.0 | 1 | NS |
| Age (years) | 74.9 ± 6 | 73.6 ± 7 | n.s. |
| BMI (kg/m²) | 26.6 ± 4 | 27 ± 4 | n.s |
| Lying SBP (mmHg) | 123.1 ± 16 | 125.9 ± 15 | .027* |
| Standing SBP (mmHg) | 118.3 ± 18 | 121.3 ± 17 | .024* |
| Lying DBP (mmHg) | 67.8 ± 9 | 69.7 ± 9 | .006* |
| Standing DBP (mmHg) | 66.7 ± 9 | 68.8 ± 9 | .003* |
| BNP (pg/ml) | 413.1 ± 480 | 286.2 ± 357 | .013* |
| EF (%) | 43.6 ± 15 | 47.9 ± 14 | .001* |
| % EF ≤ 45% | 50.6 ± 12 | 39.9 ± 12 | .001* |
| LV TDV (mL) | 144 ± 23 | 118 ± 24 | .001* |
| LV TSV (mL) | 53 ± 10 | 46 ± 9 | NS |
Abbreviations: BMI, body mass index; BNP, brain natriuretic peptide; CHF, congestive heart failure; CMP, cardiomiopathy; DBP, diastolic blood pressure; EF, ejection fraction; LV, left ventricular; NS, not significant; SBP, systolic blood pressure; TDV, total distribution volume.
Figure 1Correlation between ejection fraction (EF%) and brain natriuretic peptide (BNP) in the group with tinnitus and those without tinnitus.
Figure 2Distribution of New York Heart Association (NYHA) functional class among all patients (. (B)
Multivariate analysis of clinical correlates with the presence of tinnitus in the patients population
| Variable | Odds ratio | |
|---|---|---|
| Age > 70 years | 1.02 | 0.14 |
| Gender female | 0.97 | 0.23 |
| LVEF % < 45 | 1.28 | 0.001 |
| BNP > 200 mg/dL | 1.09 | 0.05 |
| Presbyacusis yes* | 1.02 | 0.27 |
*Bilateral loss of 30 decibels between 4,000 and 8,000 Hz.
Distribution of concomitant drug treatment
| Therapy | Yes | No | Tinnitus Yes | Tinnitus No | |
|---|---|---|---|---|---|
| ACE-inhibitors | 53.24 | 46.76 | 51.50 | 53.79 | NS |
| ARBs | 52.92 | 47.08 | 63.95 | 49.38 | .001 |
| Antiplatelets | 86.22 | 13.78 | 84.55 | 86.76 | NS |
| NSAIDs | 22.38 | 77.62 | 37.07 | 17.68 | .001 |
| Ca antagonist | 19.83 | 80.17 | 16.81 | 18.89 | NS |
| Warfarin | 19.24 | 80.76 | 20.35 | 56.55 | NS |
| Diuretics | 58.77 | 41.23 | 65.67 | 53.9 | .014 |
| Alfa-blockers | 5.45 | 94.5 | 5.60 | 4.66 | NS |
| Beta-blockers | 42.48 | 57.52 | 75.06 | 78.2 | NS |
| Statins | 5.38 | 94.62 | 7.82 | 4.63 | NS |
| Nitroderivates | 25.45 | 74.55 | 22.84 | 26.28 | NS |
| Antialdosterone drugs | 14.03 | 85.97 | 16.81 | 13.14 | NS |
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; Ca, calcium; NS, not significant; NSAIDs, nonsteroidal anti-inflammatory drugs.
Figure 3Twelve-month event-free survival in congestive heart failure (CHF) patients with or without tinnitus.